Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jasmine Lichfield"'
Autor:
John F. R. Robertson, Angelo Di Leo, Stephen Johnston, Stephen Chia, Judith M. Bliss, Robert J. Paridaens, Jasmine Lichfield, Ian Bradbury, Christine Campbell
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-12 (2021)
Abstract Endocrine therapy (ET) is recommended as first-line therapy for the majority of patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative advanced breast cancer (ABC); however, the efficacy of ET in patients wit
Externí odkaz:
https://doaj.org/article/d7d894e65aa140f485dd6e6e9833028a
Autor:
Robert Paridaens, Angelo Di Leo, Stephen Chia, Stephen R. D. Johnston, Judith M Bliss, John F.R. Robertson, Ian Bradbury, Christine M. Pierce Campbell, Jasmine Lichfield
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-12 (2021)
NPJ Breast Cancer
NPJ Breast Cancer
Endocrine therapy (ET) is recommended as first-line therapy for the majority of patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative advanced breast cancer (ABC); however, the efficacy of ET in patients with viscera
Publikováno v:
European journal of cancer (Oxford, England : 1990). 145
Background Four randomised controlled trials (RCTs) in postmenopausal women with advanced breast cancer (ABC) comparing aromatase inhibitors (AIs) versus the selective estrogen receptor modulator tamoxifen, each individually reported significantly lo
Autor:
Matthew J. Ellis, Kwok-Leung Cheung, Mehdi Fazal, Zhimin Shao, Jasmine Lichfield, Shinzaburo Noguchi, Arnold Degboe, Jackie Thirlwell, John F.R. Robertson
Publikováno v:
European journal of cancer (Oxford, England : 1990). 94
Background The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naive postmenopausal women with hormone receptor-positive (HR+) locall
Autor:
Fabian Trillsch, Carol Aghajanian, Philip Twumasi-Ankrah, Paul Rugman, Mariusz Bidziński, Aikou Okamoto, Nicoletta Colombo, Els Van Nieuwenhuysen, Jasmine Lichfield, Philipp Harter, Stephanie Lheureux, Giovanni Scambia, Maria Jesus Rubio Pérez, Alexander Reuss, Gitte-Bettina Nyvang, Mehmet Ali Vardar, Jae Weon Kim, Christian Marth, Anne Floquet
Publikováno v:
Journal of Clinical Oncology. 37:TPS5598-TPS5598
TPS5598 Background: Ovarian cancer (OC) is the leading cause of death from gynecologic cancers in US women. Despite high response rates to first-line treatment, ~70% of patients (pts) relapse within 3 years and then remain largely incurable. First-li
Publikováno v:
Annals of Oncology. 29:ix17
Autor:
Matthew J. Ellis, Kwok-Leung Cheung, Zhimin Shao, Arnold Degboe, John Forsyth Russell Robertson, Jasmine Lichfield, Shinzaburo Noguchi, Mehdi Fazal, Jackie Thirlwell
Publikováno v:
Journal of Clinical Oncology. 35:1048-1048
1048 Background: The Phase 3 randomized FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg (F) vs anastrozole 1 mg (A) in postmenopausal women with hormone receptor-positive (HR+) locally advanced or me